or Try an Advanced Search...

    Technical Analysis for ATYR - aTyr Pharma, Inc.

    Grade Last Price % Change Price Change
    F 1.56 0.00% 0.00
    ATYR closed unchanged on Monday, July 1, 2024, on 31 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ATYR trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 0.00%
    NR7 Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Up 3 Days in a Row Strength 0.00%
    Older End-of-Day Signals for ATYR ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 6 hours ago
    60 Minute Opening Range Breakdown about 10 hours ago
    Down 1% about 10 hours ago
    Rose Above 200 DMA about 10 hours ago
    10 DMA Support about 11 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ATYR Chart by TradingView
    Basic chart:

    Profile

    aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology

    Is ATYR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 5 Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025
    Jun 5 Timothy Coughlin Bought 833% More Shares In aTyr Pharma
    Jun 3 aTyr Pharma announces Nasdaq ticker symbol change to “ATYR”
    Jun 3 aTyr Pharma Announces Nasdaq Stock Ticker Symbol Change from “LIFE” to “ATYR”
    May 24 aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    May 15 aTyr Pharma to Present Poster Describing Efzofitimod’s Mechanism of Action at the American Thoracic Society 2024 International Conference
    May 14 aTyr Pharma Announces Second Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
    May 6 aTyr Pharma to Present at Upcoming Investor Conferences
    May 2 aTyr Pharma GAAP EPS of -$0.23 beats by $0.02, revenue of $0.24M beats by $0.22M
    May 2 aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
    See more ATYR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.24
    52 Week Low 1.0801
    Average Volume 469,040
    200-Day Moving Average 1.59
    50-Day Moving Average 1.73
    20-Day Moving Average 1.73
    10-Day Moving Average 1.58
    Average True Range 0.13
    RSI (14) 41.52
    ADX 22.49
    +DI 15.18
    -DI 23.40
    Chandelier Exit (Long, 3 ATRs) 1.69
    Chandelier Exit (Short, 3 ATRs) 1.80
    Upper Bollinger Bands 2.06
    Lower Bollinger Band 1.39
    Percent B (%b) 0.25
    BandWidth 39.06
    MACD Line -0.07
    MACD Signal Line -0.05
    MACD Histogram -0.025
    Fundamentals Value
    Market Cap 91.35 Million
    Num Shares 58.6 Million
    EPS -0.95
    Price-to-Earnings (P/E) Ratio -1.64
    Price-to-Sales 10.89
    Price-to-Book 1.17
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.67
    Resistance 3 (R3) 1.67 1.63 1.65
    Resistance 2 (R2) 1.63 1.61 1.63 1.64
    Resistance 1 (R1) 1.60 1.59 1.58 1.60 1.64
    Pivot Point 1.56 1.56 1.56 1.56 1.56
    Support 1 (S1) 1.53 1.54 1.51 1.53 1.48
    Support 2 (S2) 1.49 1.52 1.49 1.48
    Support 3 (S3) 1.46 1.49 1.47
    Support 4 (S4) 1.46